Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Glioma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Myasthenia Gravis 1Multiple Myeloma 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1Breast Diseases 1Astrocytoma 1Arthritis, Rheumatoid 1

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4Rituximab 4Immunoglobulins, Intravenous 4efgartigimod alfa 3Tacrolimus 3Mycophenolic Acid 3Hizentra 3HBM9161 3Data Collection 2Azathioprine 2tofacitinib 1telitacicept 1ravulizumab 1iscalimab 1gamma-Globulins 1apraclonidine 1Thymectomy 1Telemedicine 1Sugammadex 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisone 1Prednisolone 1Plasmapheresis 1Plasma Exchange 1Neurofeedback 1Neostigmine 1Muscle Stretching Exercises 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myasthenia Gravis × Leflunomide × Clear all
NCT01727193 2022-04-14

The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy

First Affiliated Hospital, Sun Yat-Sen University

Phase 3 Completed
290 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡